Digest Network Come funziona
Network
/
Società
La
Non verificato

Lantern Pharma Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaOncologiaSaluteTecnica

62 comunicati stampa

Guarda tutti i comunicati
28/07/2026
Industria
Biotecnologia
Tecnica
Salute
Farmaceutica
Oncologia
Scienza
Software
Medicina - Varie
Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
23/07/2026
Web e Social Network
Industria
Oncologia
Salute
Tecnica
Farmaceutica
Biotecnologia
Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
08/07/2026
Tecnica
Scienza
Biotecnologia
Salute
Oncologia
Industria
Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
02/06/2026
Industria
Scienza
Tecnica
Igiene alimentare
Medicina - Varie
Biotecnologia
Farmaceutica
Salute
Oncologia
Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
19/05/2026
Web e Social Network
Industria
Scienza
Tecnica
Igiene alimentare
Medicina - Varie
Biotecnologia
Farmaceutica
Salute
Oncologia
Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
15/05/2026
Mercato azionario
Biotecnologia
Tecnica
Igiene alimentare
Salute
Sanità
Farmaceutica
Oncologia
Scienza
Medicina - Varie
Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
14/05/2026
Mercato azionario
Oncologia
Salute
Tecnica
Medicina - Varie
Farmaceutica
Biotecnologia
Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
13/05/2026
Mercato del lavoro
Finanza
Software
Scienza
Farmaceutica
Information Technology
Oncologia
Tecnica
Attrezzature medico-sanitarie
Medicina - Varie
Biotecnologia
Salute
Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
11/05/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Oncologia
Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
07/05/2026
Industria
Sanità
Farmaceutica
Oncologia
Tecnica
Medicina - Varie
Scienza
Cardiologia
Biotecnologia
Management
Salute
Lantern Pharma Unveils Roadmap for withZeta.ai — Industry-First, Multi-Agentic Co-Scientist Featuring Swarm Intelligence and Computational Biology Toolkit with the Launch of ZetaSwarm™ and ZetaOmics™
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0